BioNexus Gene Lab Corp.

NASDAQ: BGLC · Real-Time Price · USD
5.27
-0.09 (-1.68%)
At close: Aug 15, 2025, 3:49 PM

BioNexus Gene Lab Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-1.6M -2.63M -355.97K 751.57K
Depreciation & Amortization
153.14K 108.42K 105.42K 108.22K
Stock-Based Compensation
n/a 511.74K n/a n/a
Other Working Capital
n/a -23.12K -129.67K 39.98K
Other Non-Cash Items
-904.46K 589.31K -38.81K 11.62K
Deferred Income Tax
n/a n/a n/a n/a
Change in Working Capital
115.4K 117.98K 833.38K -862.25K
Operating Cash Flow
-2.23M -1.3M 551.82K 9.16K
Capital Expenditures
-226.99K -149.4K -54.17K -3.16K
Cash Acquisitions
n/a n/a n/a n/a
Purchase of Investments
-571.57K -320.73K -511.71K -515.84K
Sales Maturities Of Investments
1.07M 26.15K n/a 6.39K
Other Investing Acitivies
147.98K 61.41K 115.38K 22.04K
Investing Cash Flow
418.2K -382.58K -450.5K -490.57K
Debt Repayment
n/a n/a -34.04K -26.3K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
-68.13K n/a -115.38K -22.04K
Other Financial Acitivies
144.97K 5.75M 150K -1.92K
Financial Cash Flow
144.97K 5.75M 108.17K -28.22K
Net Cash Flow
-1.63M 3.81M -5.05K -663.77K
Free Cash Flow
-2.46M -1.45M 497.65K 6K